Effectiveness of SMS Reminders on Influenza Vaccination Coverage in Patients With RA in the ART Registry
Launched by SOCIETE FRANCAISE DE RHUMATOLOGIE · Jan 25, 2022
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Design :
Randomised, controlled trial within the e-cohort population of the French ART registry (observational study)
Target population :
All participants to the e-cohort of the French ART Registry (Rheumatoid Arthritis and anti-TNF)
Gender
ALL
Eligibility criteria
- • All patients included in the French ART Registry (rheumatoid arthritis and anti-TNF) and participating to the e-cohort.
- Inclusion Criteria:
- • Adult patients with RA,
- • Patient in whom the specialist physician decides to start treatment with an anti-TNF drug, regardless of the treatment line and regardless of the anti-TNF, including infliximab, adalimumab, etanercept, certolizumab and golimumab, and their respective biosimilar according to their arrival on the market
- • Clinicians (hospital-based and private practice) who agree to adhere to the yearly renewal of the hospital prescription
- Exclusion Criteria:
- • Patient already treated by the same anti-TNF in the past (same drug)
About Societe Francaise De Rhumatologie
The Société Française de Rhumatologie (SFR) is a prominent French professional organization dedicated to advancing the field of rheumatology through research, education, and clinical practice improvement. Comprising healthcare professionals, including rheumatologists, researchers, and allied health specialists, the SFR plays a vital role in promoting scientific collaboration and facilitating clinical trials aimed at enhancing patient care outcomes. By fostering innovation and disseminating knowledge, the SFR is committed to addressing the challenges faced in rheumatologic diseases and ensuring the highest standards of care for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Le Kremlin Bicêtre, , France
Patients applied
Trial Officials
Raphaele Seror
Principal Investigator
Hôpital Bicêtre
Adeline Ruyssen-Witrand
Principal Investigator
CHU Toulouse
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials